Stockreport

Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee

Pacira BioSciences, Inc.  (PCRX) 
Last pacira biosciences, inc. earnings: 2/20 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.pacira.com
PDF -- Data demonstrates sustained clinical improvements in pain, stiffness and function for up to 156 weeks following a single administration of PCRX-201 -- BRISBANE, Cali [Read more]